Evidence map

TrialCardiovascular diabetology2025

Dapagliflozin modulates plasma lipidomic profile and urinary metabolite excretion in type 2 diabetes.

Samantha Pezzica et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

1 paper cites it

2025
2026
this papercites it
Full record →Abstract, authors, funding and every citing paper · PMID 41469882